Show simple item record

dc.contributor.authorKonstantinou, E.en
dc.contributor.authorPashalidis, Ioannisen
dc.contributor.authorKolnagou, A.en
dc.contributor.authorKontoghiorghes, G. J.en
dc.creatorKonstantinou, E.en
dc.creatorPashalidis, Ioannisen
dc.creatorKolnagou, A.en
dc.creatorKontoghiorghes, G. J.en
dc.date.accessioned2019-11-21T06:20:02Z
dc.date.available2019-11-21T06:20:02Z
dc.date.issued2011
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/55697
dc.description.abstractPresented at the 19th International Conference on Chelation, London, UK, 13-16 November 2009Preliminary spectrophotometric and potentiometric studies have shown that hydroxycarbamide or hydroxyurea (HU) can interact with copper(II) [Cu(II)], iron(II) [Fe(II)] and Fe(III) ions and form complexes, for example, a ratio of 1 HU:1 metal at pH 5. The affinity for Cu (log β1 = 3.1) and Fe (log β1 = 5) by HU is much lower than that of the Fe and Cu chelating drug deferiprone (L1), which is used for the treatment of iron overload. It is anticipated that under certain conditions of high concentrations of these metal ions such as in transfusional iron overload, the therapeutic, pharmacological and toxicological properties of HU could be affected. It is also suggested that excess chelatable and labile forms of Fe or Cu ions, such as non transferrin-bound iron (NTBI) or intracellular low molecular weight labile iron, are among the main factors that may cause variations in the therapeutic response to HU in cancer, sickle cell anemia, thalassemia intermedia and other groups of patients. Further studies are needed to clarify the interaction mechanisms of HU with metal ions in vitro, in vivo and in clinical conditions. Copyright © Informa Healthcare USA, Inc.en
dc.sourceHemoglobinen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79957447526&doi=10.3109%2f03630269.2011.578950&partnerID=40&md5=98ce9390252eed98ef5fcc594709c246
dc.subjecthydroxyureaen
dc.subjectHumansen
dc.subjectThalassemiaen
dc.subjectneoplasmen
dc.subjectconference paperen
dc.subjecttoxicityen
dc.subjectCanceren
dc.subjecttreatment responseen
dc.subjectbinding affinityen
dc.subjectmolecular weighten
dc.subjectModels, Biologicalen
dc.subjectChelationen
dc.subjectconcentration (parameters)en
dc.subjectpHen
dc.subjectCopperen
dc.subjectSpectrum Analysisen
dc.subjectChelating Agentsen
dc.subjecttransferrinen
dc.subjectironen
dc.subjectBinding, Competitiveen
dc.subjectpotentiometryen
dc.subjectspectrophotometryen
dc.subjecthydrolysisen
dc.subjectdeferiproneen
dc.subjectCopper (Cu)en
dc.subjectcopper sulfateen
dc.subjectHydroxycarbamideen
dc.subjectHydroxyurea (HU)en
dc.subjectIron (Fe)en
dc.subjectiron chelationen
dc.subjectiron overloaden
dc.subjectsickle cell anemiaen
dc.subjectSickle cell diseaseen
dc.subjectthalassemia intermediaen
dc.titleInteractions of hydroxycarbamide (Hydroxyurea) with Iron and copper: Implications on toxicity and therapeutic strategiesen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3109/03630269.2011.578950
dc.description.volume35
dc.description.issue3
dc.description.startingpage237
dc.description.endingpage246
dc.author.faculty002 Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences
dc.author.departmentΤμήμα Χημείας / Department of Chemistry
dc.type.uhtypeArticleen
dc.description.notes<p>Cited By :7</p>en
dc.source.abbreviationHemoglobinen
dc.contributor.orcidPashalidis, Ioannis [0000-0002-7587-6395]
dc.gnosis.orcid0000-0002-7587-6395


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record